Clinical Trial Update: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating LDK378 in NSCLC patients with ROS1 rearrangement (phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Yonsei University | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN